Navigation Links
Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/8/2008

EXTON, Pa., Jan. 8 /PRNewswire/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that Nicholas L. Teti, Jr., Chairman, and Declan Daly, Chief Executive Officer of Isolagen, will present at the 26th Annual JPMorgan Healthcare Conference on Thursday, January 10, 2008 at 2:00 p.m. (Pacific Time) / 11:00 a.m. (Eastern Time). The conference will be held at the Westin St. Francis Hotel in San Francisco, California.

The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.isolagen.com. An archive of the presentation will be available on the Company's website for 30 days following the conference.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit http://www.isolagen.com.

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.


'/>"/>
SOURCE Isolagen(TM), Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen Modifies Ongoing Clinical Program for Acne Scars
2. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
3. Isolagen, Inc. Postpones Annual Meeting
4. Emageon to Present at the 26th Annual JPMorgan Healthcare Conference
5. Warner Chilcott to Present at the 26th Annual JPMorgan Healthcare Conference
6. Covance to Present at 26th Annual JPMorgan Healthcare Conference
7. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
8. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
9. DaVita Inc. to Present at JPMorgan Healthcare Conference
10. Hologic to Present at the 26th Annual JP Morgan Healthcare Conference
11. WebMD to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... Phytomer USA is pleased to introduce ... Account Manager, Smith’s role is to provide excellent customer service, support, training and ... Phytomer Group. Smith comes to Phytomer with a wealth of industry experience including roles ...
(Date:4/28/2017)... ... April 28, 2017 , ... The National Campaign to ... the Access to Contraception for Women Servicemembers and Dependents Act of 2017. The ... will help to ensure that all members of the Armed Forces receive high ...
(Date:4/28/2017)... ... , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced today ... outlook as “stable.” At the same time, the ratings agency cautioned that the company’s ... below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed to ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Radiology Business Management Association (RBMA) ... The annual board election process has been in place since the RBMA was founded ... Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the ...
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 The Mobile X-Ray product segment ... healthy CAGR during the forecast period Mobile X-Ray ... global digital mobile X-Ray devices market, which is estimated to ... expanding at a CAGR of 7% over the forecast period. ... of more than US$ 100 Mn in 2017 over 2016. ...
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 19, 2017  New research provides evidence that an old ... to a study released today that will be presented at ... in Boston , April 22 to 28, ... of Parkinson,s disease, the oral drug levodopa has long been ... But as the disease progresses, the effects of the medication ...
Breaking Medicine Technology: